BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nogapendekin alfa inbakicept (Anktiva) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nogapendekin alfa inbakicept (Anktiva)\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06829823-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT06
 829823)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2\, Bladder Canc
 er.\nStudy: Clinical Trial of Ablation Therapy in Participants With Interm
 ediate-Risk Non-Muscle Invasive Papillary Bladder Cancer\nEstimated primar
 y completion: November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06829823
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161545-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT06
 161545)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: Pembr
 olizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resec
 table Head and Neck Squamous Cell Carcinoma\nEstimated primary completion:
  1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nog
 apendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06161545
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06253494-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 1/2 readout est. (NCT
 06253494)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 1/2.\nStudy: Pem
 brolizumab\, Lenvatinib and IL-15 Superagonist N-803 in Combination With H
 ER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants
  With Advanced or Metastatic Endometrial Cancer\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06253494
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123727-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 123727)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: A Stu
 dy to Examine Anktiva for the Treatment of COVID-19.\nEstimated primary co
 mpletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07123727
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06710288-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT06
 710288)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: A Pha
 se 2\, Open-label\, Single-arm Study Of Autologous M-CENK Adoptive Cell Th
 erapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Pa
 rticipants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer\nEs
 timated primary completion: May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06710288
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05096663-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2/3 readout est. (NCT
 05096663)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2/3\, Non-Small 
 Cell Lung Cancer.\nStudy: Testing the Use of Combination Immunotherapy Tre
 atment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment fo
 r Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05096663
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05419011-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT05
 419011)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: Testi
 ng a Combination of Vaccines for Cancer Prevention in Lynch Syndrome\nEsti
 mated primary completion: 1 July 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05419011
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06149481-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 1/2 readout est. (NCT
 06149481)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 1/2.\nStudy: Pha
 se I/II Study of the Combination Immunotherapy Regimen: SX-682\, TriAdeno 
 Vaccine\, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Col
 orectal Cancer (mCRC)\nEstimated primary completion: 31 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakic
 ept-anktiva#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06149481
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07145164-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 145164)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: Inter
 leukin-15 to Promote Post-ART Control of HIV\nEstimated primary completion
 : December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/noga
 pendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07145164
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477366-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 477366)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: Study
  of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-H
 odgkin Lymphoma\nEstimated primary completion: December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-ankt
 iva#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07477366
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217496-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 1 readout est. (NCT07
 217496)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 1\, Bladder Canc
 er.\nStudy: N-803 in Combination With Pembrolizumab and Enfortumab Vedotin
  for Treatment of Urothelial Cancer\nEstimated primary completion: January
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nogapendekin-a
 lfa-inbakicept-anktiva#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07217496
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085338-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 085338)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: A Pha
 se II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmuno
 therapy Backbone for the Treatment of Patients With Relapsed or Refractory
  Neuroblastoma\nEstimated primary completion: 1 February 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-ank
 tiva#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07085338
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783789-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20280512
DTEND;VALUE=DATE:20280513
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 783789)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: NAI P
 lus Standard of Care Compared To SOC Alone Plus Standard of Care in Critic
 ally Ill Adults With Sepsis\nEstimated primary completion: 12 May 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbak
 icept-anktiva#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07783789
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07574541-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 574541)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: Multi
 targeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno
 ) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Lo
 calized Prostate Cancer Undergoing Active Surveillance\nEstimated primary 
 completion: 15 June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07574541
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745908-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 3 readout est. (NCT06
 745908)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 3\, Non-Small Ce
 ll Lung Cancer.\nStudy: Clinical Trial of N-803 Plus Tislelizumab or Prior
  Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monothe
 rapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cance
 r Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy\nEst
 imated primary completion: September 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06745908
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686380-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20290130
DTEND;VALUE=DATE:20290131
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 686380)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: IL-15
  Superagonist With or Without Vaccine in Biochemically Recurrent Prostate 
 Cancer After Previous Stereotactic Body Radiation Therapy\nEstimated prima
 ry completion: 30 January 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07686380
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756593-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20290414
DTEND;VALUE=DATE:20290415
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 1 readout est. (NCT07
 756593)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 1.\nStudy: Sipul
 eucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway M
 odulation Resistant (mAPMR) Prostate Cancer\nEstimated primary completion:
  14 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nogap
 endekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07756593
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT03
 228667)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2\, Non-Small Ce
 ll Lung Cancer.\nStudy: QUILT-3.055: A Study of Combination Immunotherapie
 s in Patients Who Have Previously Received Treatment With Immune Checkpoin
 t Inhibitors\nEstimated primary completion: 31 August 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiv
 a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 228667
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06061809-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT06
 061809)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: N-803
  and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive G
 lioblastoma\nEstimated primary completion: 31 December 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-ankti
 va#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6061809
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261657-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 1 readout est. (NCT07
 261657)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 1.\nStudy: N-803
  in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Lipos
 arcoma Previously Treated With Adoptive Cellular Therapy\nEstimated primar
 y completion: 2 September 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07261657
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07628062-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 628062)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: Phase
  2 Study of NAI\, HPV Vaccine\, and Nab-Paclitaxel in HPV-Positive Orophar
 yngeal Cancer Followed by De-Intensified Radiation Compared With Standard 
 Chemoradiation\nEstimated primary completion: 31 December 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-an
 ktiva#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07628062
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355205-2051@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20320731
DTEND;VALUE=DATE:20320801
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 1/2 readout est. (NCT
 07355205)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 1/2\, Non-Small 
 Cell Lung Cancer.\nStudy: First-Line Ipilimumab Plus Nivolumab and Nogapen
 dekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-S
 mall Cell Lung Cancer\nEstimated primary completion: 31 July 2032. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept
 -anktiva#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07355205
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
